{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kaletsch A"],"funding":["Deutsche Forschungsgemeinschaft","Forschungskommission der Medizinischen Fakultät der HHU","Dr.-Brigitte- &amp;Constanze-Wegener-Stiftung"],"pagination":["100"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6069857"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10(1)"],"pubmed_abstract":["<h4>Background</h4>Histone deacetylase inhibitors (HDACi) are promising anti-cancer drugs that could also be employed for urothelial carcinoma (UC) therapy. It is unclear, however, whether inhibition of all 11 zinc-dependent HDACs or of individual enzymes is more efficacious and specific. Here, we investigated the novel HDACi 19i (LMK235) with presumed preferential activity against class IIA HDAC4/5 in comparison to the pan-HDACi vorinostat (SAHA) and the HDAC4-specific HDACi TMP269 in UC cell lines with basal expression of HDAC4 and characterized two HDAC4-overexpressing UC cell lines.<h4>Methods</h4>Cytotoxic concentrations 50% (CC<sub>50</sub>s) for HDACi were determined by MTT assay and high-content analysis-based fluorescent live/dead assay in UC cell lines with different expression o"],"journal":["Clinical epigenetics"],"pubmed_title":["Effects of novel HDAC inhibitors on urothelial carcinoma cells."],"pmcid":["PMC6069857"],"funding_grant_id":["11","42/2015","NI 1398/1-1"],"pubmed_authors":["Schulz WA","Hansen FK","Kassack MU","Pinkerneil M","Wang C","Kurz T","Niegisch G","Gohlke H","Kaletsch A","Hanenberg H","Hoffmann MJ","Gertzen C","Wiek C","Jaguva Vasudevan AA"],"additional_accession":[]},"is_claimable":false,"name":"Effects of novel HDAC inhibitors on urothelial carcinoma cells.","description":"<h4>Background</h4>Histone deacetylase inhibitors (HDACi) are promising anti-cancer drugs that could also be employed for urothelial carcinoma (UC) therapy. It is unclear, however, whether inhibition of all 11 zinc-dependent HDACs or of individual enzymes is more efficacious and specific. Here, we investigated the novel HDACi 19i (LMK235) with presumed preferential activity against class IIA HDAC4/5 in comparison to the pan-HDACi vorinostat (SAHA) and the HDAC4-specific HDACi TMP269 in UC cell lines with basal expression of HDAC4 and characterized two HDAC4-overexpressing UC cell lines.<h4>Methods</h4>Cytotoxic concentrations 50% (CC<sub>50</sub>s) for HDACi were determined by MTT assay and high-content analysis-based fluorescent live/dead assay in UC cell lines with different expression o","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Jul","modification":"2025-04-04T20:30:53.606Z","creation":"2019-03-26T23:49:58Z"},"accession":"S-EPMC6069857","cross_references":{"pubmed":["30064501"],"doi":["10.1186/s13148-018-0531-y"]}}